Specific Biologics Closes 35 Million Dollar Series A

Company Specific Biologics Event Type Series A financing Modality Dualase nuclease genome editing (repeat excision) Asset C9ORF72 repeat-expansion editing candidate Target C9ORF72 repeat expansion Disease Area Amyotrophic lateral sclerosis Summary Specific Biologics announced November 2 the close of an oversubscribed US$35 million Series A led…